Please assess the completion status of the following clinical trial:

Trial Title: IGF-1 Therapy in Patients With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of cystic fibrosis as proven by either sweat chloride or DNA analysis.~* Age \>= 18 yr.~* Tanner stage: Femake Breasts: 4-5 Male Genitalia: 4-5~Exclusion criteria:~* Hemoglobin A1C \> 8.5 %~* Diabetic retinopathy~* Obstructive sleep apnea~* Respiratory failure requiring mechanical ventilation.~* Status post pulmonary transplantation.~* Concurrent or recent (within past 6 months) receipt of human growth hormone.~* History of adverse side effects to growth hormone other than carbohydrate intolerance.~* Pregnancy or attempting pregnancy.~* Women who are breast feeding.~* Sexually active women who refuse to use or are incapable of responsibly using reliable contraception.~* Proven non compliance with medical regimens.~* Inability or refusal to take subcutaneous injections.~* Known allergy to components in the IGF-I preparation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IGF-1 (Type: EXPERIMENTAL): Recombinant human IGF-1
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).